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Schistosoma mansoni infection or associated products are able to down-modulate the type 1 CD4+ T cell inflam-
matory response characteristic of autoimmune diseases. In this study, we evaluated how S. mansoni antigens altered 
the immune response that was induced by the soluble Leishmania antigen (SLA) from cutaneous leishmaniasis (CL) 
patients. Cytokines were measured from the supernatants of peripheral blood mononuclear cell cultures stimulated 
with SLA. This was performed using the sandwich enzyme linked immunosorbent assay technique in the presence 
or absence of S. mansoni recombinant antigens Sm29, SmTSP-2 and PIII. The addition of S. mansoni antigens 
to the cultures resulted in the reduction of interferon gamma (IFN-γ) levels in 37-50% of patients. Although to a 
lesser extent, the antigens were also able to decrease the production of tumour necrosis factor-alpha (TNF-α). We 
compared patients that either had or did not have reduction in IFN-γ and TNF-α production in cultures stimulated 
with SLA in the presence of S. mansoni antigens. We found that there was no significant difference in the levels of 
interleukin (IL)-10 and IL-5 in response to S. mansoni antigens between the groups. The antigens used in this study 
down-modulated the in vitro proinflammatory response induced by SLA in a group of CL patients through a cur-
rently undefined mechanism.
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Leishmaniasis is an infectious disease caused by a 
protozoan from the genus Leishmania spp. It is one of 
the most common infectious diseases, affecting 12 mil-
lion people worldwide with an incidence of 1.5 million 
cases per year (Desjeux 2001). Four different forms of 
tegumentary leishmaniasis are described: cutaneous, 
mucosal, diffuse and disseminated leishmaniasis. Cuta-
neous leishmaniasis (CL) is the most common clinical 
manifestation, characterised by one to several skin le-
sions in exposed areas, with an absence or small number 
of parasites (Jones et al. 1987, Bogdan et al. 1996). 
CL is endemic in many regions of Central and South 
America (Jones et al. 1987). In the state of Bahia (BA), in 
Brazil, the number of CL cases reaches 23.4 per 100,000 
inhabitants (SVS/MS 2010).
Some evidence has suggested that the immune re-
sponse contributes to the tissue injury characteristic of 
CL. Leishmania donovani infection is controlled by type 
1 CD4+ T cell (Th1) immune response. The Th1 response 
is important to produce interferon-gamma (IFN-γ) and 
activate tissue macrophages (Murray & Cartelli 1983, 
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Murray et al. 1983). However in the presence of a strong of 
a Th1 response, there is an increased production of IFN-γ 
and tumour necrosis factor-alpha (TNF-α). This increased 
production of inflammatory cytokines leads to intense 
tissue damage resulting in the development of CL and 
mucosal leishmaniasis (Ribeiro-de-Jesus et al. 1998).
Bacellar et al. (2002) showed that mononuclear cells 
from mucosal leishmaniasis patients have a decreased 
ability to produce and to respond to interleukin (IL)-10 
after restimulation with Leishmania braziliensis anti-
gen in vitro. Moreover, neutralisation of IL-10 enhanced 
IFN-γ production by peripheral blood mononuclear cells 
(PBMC) and also increased lymphocyte proliferation in 
patients with CL (Rocha et al. 1999). The regulatory cy-
tokine IL-10 seems to play a major role in modulating the 
inflammatory responses associated with CL development. 
However, this cytokine maintains latency in murine mod-
els of Leishmania major infection (Belkaid et al. 2001).
In recent years, studies have demonstrated that hel-
minth infections or products from their infections have 
the potential to modulate Th2-immune responses that 
result in the pathology of allergic diseases (Araujo et al. 
2000, 2004, Cooper et al. 2003). Our research group has 
demonstrated that asthmatic patients who are infected 
with Schistosoma mansoni have a less severe course of 
asthma and an inhibition of the Th2 inflammatory re-
sponse that seems to be mediated by IL-10 (Medeiros 
et al. 2004, Cardoso et al. 2006). In a murine model 
of ovalbumin (OVA)-induced airway inflammation, S. 
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mansoni antigens reduced the allergic Th2 response 
(Cardoso et al. 2010). Other recent experimental studies 
have shown that S. mansoni infection or parasite prod-
ucts induce regulatory cells and cytokines that are able 
to prevent an autoimmune Th1 inflammatory response 
seen in diseases such as type-I diabetes, encephalomy-
elitis and psoriasis (Cooke et al. 1999, Sewell et al. 2003, 
Atochina & Harn 2006).
Considering the demonstrated ability of S. mansoni an-
tigens to prevent some Th1-mediated diseases, this study 
aimed to evaluate the effects of S. mansoni antigens on the 
immune response induced by the soluble Leishmania an-
tigen (SLA) in CL patients. We examined IFN-γ, TNF-α, 
IL-10 and IL-5 production by PBMC stimulated in vitro 
with SLA in the presence or absence of the S. mansoni an-
tigens Sm29, tetraspanin 2 (SmTSP-2) and PIII, a fraction 
of S. mansoni soluble adult worm antigen (SWAP).
PATIENTS, MATERIALS AND METHODS
This study evaluated the ability of S. mansoni an-
tigens to alter cytokine production by PBMC from pa-
tients with CL, which was assessed based on the PBMC 
cytokine response to SLA in vitro. The study included 
22 individuals living in the endemic area of Corte de 
Pedra, BA. They attended the local healthcare facility 
from September 2009-October 2010 and agreed to par-
ticipate in this study.
All patients included in the study donated blood for 
PBMC cultures, which were stimulated with SLA in the 
presence or absence of S. mansoni antigens.
S. mansoni antigens - The antigens used in this study 
included the recombinant proteins Sm29 and SmTSP-2 
and a fraction of S. mansoni SWAP obtained by anionic 
chromatography referred to in this study as PIII. The 
recombinant proteins were cloned in Escherichia coli. 
They were tested for lipopolysaccharide (LPS) con-
tamination using a commercially available Chromoge-
nic LAL Kit (Cambrex). The levels of LPS in Sm29 and 
SmTSP-2 were below 0.25 ng/mL. In order to neutral-
ize the potential effects of LPS, polymyxin B was added 
to the cell cultures every 12 h as previously performed 
(Cardoso et al. 2007).
PBMC cultures and cytokine measurements - PBMCs 
were obtained using a Ficoll-Hypaque gradient. PBMCs 
were cultured at a concentration of 3 x 106 cells/mL in 
Roswell Park Memorial Institute 1640 containing 10% 
normal human serum (AB+, heat inactivated), 100 U/mL 
penicillin, 100 mg/mL streptomycin, 2mM L-glutamine 
and 30 mM HEPES (Life Technologies Gibco-BRL, 
Gaithersburg, MD). Cells were cultured with the anti-
gens Sm29, SmTSP-2 and PIII at a concentration of 5 µg/
mL in the presence or absence of SLA (5 µg/mL). The 
levels of IFN-γ, TNF-α, IL-10 and IL-5 were measured 
in the supernatants of PBMC cultures as determined by 
sandwich enzyme linked immunosorbent assay. The re-
sults are expressed as picograms per millilitre (pg/mL) 
based on a standard curve.
Statistical analyses - Statistics were analysed utilis-
ing the software Statistical Package for Social Science 
version 9.0 for Windows. Statistical differences between 
the means of cytokine levels were analysed using Wil-
coxon matched pairs test or Mann-Whitney test, as in-
dicated. Fisher’s exact test was used to compare propor-
tions. Statistical significance was established at the 95% 
confidence interval.
The Ethical Committee of Climério de Oliveira Ma-
ternity, Federal University of Bahia, approved the pres-
ent study. Informed consent was obtained from all study 
participants or their legal guardians.
RESULTS
The demographic information for CL patients includ-
ed in the study is shown in Table I. A total of 22 patients 
with CL were enrolled in this study: 13 were male and 
nine were female, with a mean age of 26.2 ± 9.8 years 
(range 6-48 years) (Table I). The majority of patients pre-
sented with a single lesion (77.3%) and the median lesions 
size was 100 mm² (interquartile range, 35.0-276.0).
To test the ability of S. mansoni antigens, Sm29, 
SmTSP-2 and PIII, to down-modulate IFN-γ and TNF-α 
production, these antigens were added into SLA-stimu-
lated PBMC cultures from CL patients. There were no 
significant differences between the mean levels of IFN-γ 
detected in supernatants of PBMC cultures stimulated 
with SLA alone [mean ± standard error (SEM) = 3,568 
± 1,184 pg/mL] or SLA plus S. mansoni antigens rSm29, 
SmTSP-2 and PIII (3,819 ± 1,144 pg/mL, 4,822 ± 1,373 
pg/mL and 3,466 ± 308.5 pg/mL, respectively) (Fig. 
1A-C). Likewise, no difference was observed in levels of 
TNF-α in the supernatants of PBMC cultures stimulated 
with SLA alone (2,314 ± 318.5 pg/mL) and SLA plus 
S. mansoni antigens Sm29, SmTSP-2 and PIII (2,638 ± 
325.5 pg/mL, 2,314 ± 381.5 pg/mL and 2,167 ± 304.4 pg/
mL, respectively) (Fig. 1A-C).
A significant increase in the concentration of IL-
10 was observed when Sm29 was added to the cultures 
(mean ± SEM = 528.8 ± 151.8 pg/mL) as compared to 
SLA alone (170.3 ± 70.7 pg/mL, p < 0.0005). The dif-
ference in mean levels of IL-10 was not significant for 
the two other S. mansoni antigens used in this study 
SmTSP-2 and PIII (175.2 ± 64.6 pg/mL and 172.6 ± 53.4 
pg/mL, respectively) (Fig. 1D-F).
TABLE I
Demographic characteristics of the cutaneous  
leishmaniasis patients included in the study
Characteristics
(n = 22) Values
Age (years) (mean ± SD) 26.2 ± 9.8
Sex (female/male) 9/13
Lesions [n (%)]
1
≥ 2 
17 (77.3)
5 (22.7)
Size of lesion [median mm² (IQR)] 100 (35-276)
IQR: interquatile range; SD: standard deviation.
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Additionally, we assessed IL-5 production and found 
no significant differences between the mean levels of this 
cytokine detected in the supernatants of PBMC cultures 
stimulated with SLA alone (mean ± SEM = 66.4 ± 23 pg/
mL) or SLA plus S. mansoni antigens rSm29, SmTSP-2 
and PIII (62.5 ± 22.3 pg/mL, 56.7 ± 20.3 pg/mL and 89.7 
± 29.4 pg/mL, respectively, p > 0.05) (Fig. 1D-F).
There was, however, a group of patients who pre-
sented with reduced levels of IFN-γ and TNF-α and in-
creased levels of IL-10 and IL-5 when Sm29, SmTSP-2 
and PIII were added to the cultures stimulated with 
SLA. The frequency of individuals with reduced IFN-γ 
production as a result of the presence of Sm29, SmTSP-2 
and PIII were 40.9%, 36.8% and 50%, respectively. Re-
duction in TNF-α levels was found in 15.8%, 26.3% and 
27.3% of CL patients when Sm29, SmTSP-2 and PIII 
were added to the PBMC cultures stimulated with SLA. 
The addition of Sm29, SmTSP-2 and PIII to the cultures 
resulted in increased levels of IL-10 in 68.4%, 52.6% 
and 47.4% of patients, respectively. Additionally, levels 
of IL-5 were increased in 21%, 15.8% and 26.3% of pa-
tients when Sm29, SmTSP-2 and PIII were added to the 
cultures stimulated with SLA.
Patients that showed varying levels of cytokine pro-
duction following the addition of the S. mansoni antigens 
to the cultures stimulated with SLA were further analysed 
individually. The levels (mean ± SEM) of IFN-γ, TNF-α, 
IL-10 and IL-5 in the supernatants of PBMC cultures 
stimulated with SLA in the presence or absence of Sm29, 
SmTSP-2 and PIII are shown in Fig. 2. The mean levels of 
IFN-γ (Fig. 2A) diminished from 5,379 ± 1,253 pg/mL to 
1,093 ± 540.3 pg/mL (79.7% reduction) to 1,739 ± 920.7 
pg/mL (67.7% reduction) and to 2,409 ± 1,357 pg/mL 
(55.3% reduction) in the presence of Sm29, SmTSP-2 and 
PIII, respectively, compared to SLA alone (p < 0.05).
The levels of TNF-α (Fig. 2B) dropped from 2,090 
± 210.8 pg/mL in PBMC cultures stimulated with SLA 
to 950.9 ± 96.1 pg/mL (54.5% reduction), 1,823 ± 450.8 
pg/mL (12.7% reduction) and 1,411 ± 356 pg/mL (32.5% 
reduction) in the presence of Sm29, SmTSP-2 and PIII, 
respectively. On the other hand, the levels of IL-10 (Fig. 
2C) increased from 156.6 ± 46.9-693.6 ± 204 pg/mL 
(342.9% increase after addition of Sm29), to 195.7 ± 77.9 
pg/mL (25% increase in response to SmTSP-2) and to 
216.7 ± 77.9 pg/mL (38.4% increase in response to PIII) 
(p < 0.05). There was also an increase in the levels of IL-5 
from 107.4 ± 30-177.3 ± 62.9 pg/mL (65% increase) to 
154.7 ± 71.2 pg/mL (44% increase) and to 301 ± 16.7 pg/
mL (180% increase) when Sm29, SmTSP-2 and PIII were 
added to the cultures, respectively (p < 0.05) (Fig. 2D).
Correlations between the levels of the pro-inflamma-
tory cytokines IFN-γ and TNF-α with the anti-inflam-
matory cytokines IL-10 and IL-5 were analysed. There 
was a positive correlation between the levels of TNF-α 
Fig. 1: levels of interferon gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α) in cultures stimulated with soluble Leishmania antigen 
(SLA) in the presence or absence of Schistosoma mansoni antigens Sm29 (A), SmTSP2 (B) and PIII (C). Levels of interleukin (IL)-10 and 
IL-5 in cultures stimulated with SLA in the presence or absence of S. mansoni antigens Sm29 (D), SmTSP-2 (E) and PIII (F). Cytokines were 
measured using enzyme linked immunosorbent assay sandwich technique. Asterisk means p < 0.0005. SLA vs. SLA + Sm29 (Wilcoxon 
matched pairs test).
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and IL-5 when Sm29 (r = 0.6; p = 0.004) and SmTSP2 (r = 
0.5; p = 0.004) were added to the cultures. No significant 
correlation was observed between levels of IFN-γ and 
IL-5 or IFN-γ and IL-10. Additionally, there was no corre-
lation between the levels of TNF-α and IL-10 when the S. 
mansoni antigens were added to the cultures (not shown).
In order to evaluate if the severity of leishmaniasis, 
measured by number and size of lesions, interferes with 
the response to S. mansoni antigens in vitro, we analysed 
the frequency of CL patients who presented or did not 
present reduction in the levels of IFN-γ and TNF-α ac-
cording to these specified parameters (Tables II, III). Pa-
tients whose levels of IFN-γ were unaffected by the ad-
dition of SmTSP-2 to the cultures had smaller lesion size 
compared to patients who had reduced levels of IFN-γ (p 
< 0.05) (Table II). There was no significant difference in 
other assessed clinical parameters, such as number of le-
sions and number of pentavalent antimony Sb(v) courses, 
between these two groups of patients when S. mansoni 
antigens were added to the PBMC cultures.
Additionally, patients who either had reduced levels 
of IFN-γ and TNF-α or not when S. mansoni antigens 
were added to the cultures were evaluated regarding the 
levels of IL-10 and IL-5. Patients with reduced IFN-γ 
production as a result of the addition of S. mansoni anti-
gens and those patients in whom IFN-γ production was 
unaffected had similar frequencies of individuals who 
displayed increased levels of IL-10 and IL-5 in response 
to S. mansoni antigens (p > 0.05) (Table II).
The frequency of patients who had increased lev-
els of IL-10 and IL-5 when the S. mansoni antigens 
were added to the cultures did not differ between the 
group of patients who either had a reduction in TNF-α 
production or not in the presence of S. mansoni anti-
gens (p > 0.05) (Table III).
Finally, we compared the levels of IFN-γ and TNF-α 
in response to SLA between the group of patients who 
had reduced levels of these cytokines by the addition of 
S. mansoni to the cultures and those who did not have 
reduced cytokine production. The levels of TNF-α were 
similar between groups (p > 0.05) (Table III). However, 
the levels of IFN-γ were higher in patients who had re-
duced IFN-γ production in response to PIII (6,046 ± 
6,925 pg/mL) as compared to those who did not have 
reduced production of IFN-γ when PIII was added to 
the culture (1,176 ± 1,877 pg/mL, p = 0.05).
Fig. 2: levels of interferon gamma (IFN-γ) (A), tumour necrosis factor-alpha (TNF-α) (B), interleukin (IL)-10 (C) and IL-5 (D) in peripheral blood 
mononuclear cells (PBMC) supernatants of cutaneous leishmaniasis patients stimulated with soluble Leishmania antigen (SLA) in vitro in the pres-
ence and absence of the Schistosoma mansoni antigens Sm29, SmTSP-2 and PIII. Cytokines were measured using enzyme linked immunosorbent 
assay sandwich technique. The figures represent the mean ± standard deviation of cytokine levels in individuals who presented with decreased in 
the levels of IFN-γ and TNF-α and increased levels of IL-10 and IL-5 when S. mansoni antigens were added to the cultures. Asterisk means p < 0.05. 
SLA vs. SLA + S. mansoni antigens (Wilcoxon matched pairs test) (the percentage of reduction is indicated next to the asterisk).
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TABLE II
Frequency of individuals who presented reduction in the levels of interferon gamma (IFN-γ) by the presence of Schistosoma  
mansoni antigens in culture stimulated with soluble Leishmania antigen (SLA) according to clinical and immunological features
Patients who presented
inhibition in IFN-γ production
Patients who did not present
inhibition in IFN-γ production
Sm29 SmTSP-2 PIII Sm29 SmTSP-2 PIII
Lesions [n (%)]
1 7/9 (77.9) 5/7 (71.4) 7/11 (63.6) 10/13 (76.9) 11/12 (91.7) 9/10 (90)
≥ 2 2/9 (22.2) 2/7 (28.6) 4/11 (36.4) 3/13 (23.1) 1/12 (8.3) 1/10 (10)
Lesions size (mm2)
0-99 4/9 (44.5) 3/7 (42.9) 7/11 (63.6) 6/13 (46.1) 11/12 (91.7)a 5/10 (50)
≥ 100 5/9 (55.6) 4/7 (57.1) 4/11 (36.4) 6/13 (46.1) 1/12 (8.3) 4/10 (40)
No data 0 (0) 0 (0) 0 (0) 1/13 (7.7) 0 (0) 1/10 (10)
Sb(v) courses [n (%)]
1 2/9 (22.2) 2/7 (28.6) 3/11(27.3) 3/13 (23.1) 3/12 (25) 2/10 (20)
≥ 2 5/9 (55.6) 1/7 (14.3) 5/11 (45.5) 3/13 (23.1) 4/12 (33.3) 2/10 (20)
No data 7/9 (77.9) 5/7 (71.4) 7/11 (63.6) 10/13 (76.9) 11/12 (91.7) 9/10 (90)
IFN-γ levels in  
response to SLA (pg/mL) 3,766 ± 6,154 4,353 ± 4,426 6,046 ± 6,925a 3,430 ± 5,351 3,852 ± 6,722 1,176 ± 1,877
Cytokines
Increase in IL-10 5/6 (83.3) 3/7 (42.8) 4/8 (50) 8/13 (61.5) 7/12 (58.3) 4/10 (40)
Increase in IL-5 1/6 (16.7) 1/7 (14.3) 1/8 (12.5) 3/13 (23) 2/12 (16.7) 3/10 (30)
a: patients who presented inhibition of IFN-γ production vs. patients who did not reduce the levels of this cytokine when SmTSP-2 
and PIII was added to the culture (p < 0.05; Fisher’s exact test); IL: interleukin; Sb(v): pentavalent antimony.
TABLE III
Frequency of individuals who presented reduction in the levels of tumour necrosis factor-alpha (TNF-α) by the presence of 
Schistosoma mansoni antigens in culture stimulated with soluble Leishmania antigen (SLA) according to clinical  
and immunological features
Patients who presented
inhibition in IFN-α production
Patients who did not present
inhibition in IFN-α production
Sm29 SmTSP-2 PIII Sm29 SmTSP-2 PIII
Lesions [n (%)]
1 3/3 (100) 4/5 (80) 4/6 (66.6) 13/16 (81.3) 12/14 (85.7) 12/16 (75)
≥ 2 0/3 (0) 1/5 (20) 1/6 (16.7) 3/16 (18.8) 2/14 (14.3) 2/16 ( 12.5)
No data 0/3 (0) 0/5 (0) 1/6 (16.7) 0/16 (0) 0/14 (0) 2/16 (12.5)
Lesions size (mm2)
0-99 2/3 (66.7) 2/5 (40) 1/6 (16.7) 7/16 (43.8) 8/14 (57.1) 6/16 (37.5)
≥ 100 1/3 (33.3) 3/5 (60) 4/6 (66.6) 8/16 (50) 5/14 (35.7) 7/16 (43.8)
No data 0/3 (0) 0/5 (0) 1/6 (16.7) 1/16 (6.3) 1/14 (7.1) 3/16 (18.8)
Sb(v) courses [n (%)]
1 1/3 (33.3) 3/5 (60) 1/6 (16.7) 8/16 (50) 6/14 (42.9) 3/16 (18.8)
≥ 2 1/3 (33.3) 2/5 (40) 2/6 (33.3) 4/16 (25) 3/14 (21.4) 7/16 (43.8)
No data 1/3 (33.3) 0/5 (0) 2/6 (33.3) 4/16 (25) 5/14 (35.7) 6/16 (37.5)
TNF-α  levels in
response to SLA (pg/mL) 1,678 ± 188.4 2,168 ± 947.2 2,051 ± 897.8 2,433 ± 1,487 2,366 ± 1,543 2,119 ± 1,585
Cytokines
Increase in IL-10 3/3 (100) 2/5 (40) 1/5 (20) 10/16 (62.5) 8/14 (57.1) 8/14 (57.1)
Increase in IL-5 0/3 (0) 1/5 (20) 0/5 (0) 4/16 (25) 2/14 (14.3) 5/14 (35.7)
patients who presented inhibition of TNF-α production vs. patients who did not reduce the levels of this cytokine when S. man-
soni antigens were added to the culture (p > 0.05; Fisher’s exact test); IL: interleukin; Sb(v): pentavalent antimony.
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DISCUSSION
The present study evaluated the ability of S. mansoni 
antigens to down-modulate the inflammatory response 
to SLA in PBMC of CL patients. We showed that the 
addition of the S. mansoni antigens, Sm29, SmTSP-2 
and PIII, to PBMC cultures of patients infected with L. 
braziliensis stimulated with SLA reduced IFN-γ and 
TNF-α; conversely, these cells produced increased levels 
of IL-10 as seen in a considerable number of patients.
There is evidence that Schistosoma spp infection or 
its products protect against the development of Th2-me-
diated diseases in humans and mice (Araujo et al. 2000, 
2004, Medeiros et al. 2003, 2004, Pacifico et al. 2009). 
Moreover, in experimental studies, it has been shown 
that S. mansoni infection or its parasite products are able 
to down-modulate the Th1 inflammatory response that 
is implicated in several autoimmune diseases, such as 
type-I diabetes, encephalomyelitis and psoriasis (Cooke 
et al. 1999, Sewell et al. 2003, Atochina & Harn 2006).
Our group has performed studies in an attempt to 
identify S. mansoni antigens with regulatory properties 
that may enable them to down-regulate inflammation 
associated with particular immune-mediated diseases. 
For instance, in experimental models of OVA-induced 
asthma, the injection of Sm22.6, PIII or Sm29 antigens 
resulted in a decrease in Th2-inflammatory mediators 
involved with disease pathology (Cardoso et al. 2010). 
Mechanisms underlying this modulation appear to in-
clude regulatory pathways induced by S. mansoni or their 
products. Indeed, it has been shown that during chronic 
S. mansoni infection, innate immune cells, T cells and T 
regulatory cells are able to produce IL-10 (Araujo et al. 
2004, Hesse et al. 2004, Oliveira et al. 2009).
It has been demonstrated that S. mansoni phospha-
tidilserine (PS) has the ability to stimulate antigen-pre-
senting cells from naïve individuals to produce IL-10 via 
Toll-like receptor-2 stimulation which promotes T-regu-
latory cell maturation (van der Kleij et al. 2002). More-
over, it has been demonstrated that the immune response 
to the Schistosoma haematobium Toll-like ligand antigen, 
lyso-PS, results in the production of IL-10 by cells of the 
innate immune system in non-infected children (van der 
Kleij et al. 2004). This suggests that there are molecular 
patterns associated with helminths that are involved in the 
down-regulation of the immune response.
There is evidence that an exacerbated Th1 immune 
response with high production of IFN-γ and TNF-α, as 
well a lack of regulatory response, is associated with le-
sion development in CL and mucosal leishmaniasis, as 
reviewed by Ribeiro-de-Jesus et al. (2008). On the other 
hand, these cytokines are fundamental to parasite kill-
ing (Liew et al. 1990). IL-10, on the other hand, is able 
to control the exacerbated Th1 inflammatory response, 
despite data that show it could be responsible for para-
site maintenance (Belkaid et al. 2001). An equilibrate 
immune response may be the key to a harmless host-
parasite relationship.
Studies of patients with concurrent infections of L. 
braziliensis and a helminth infection have shown that 
these patients tend to present with smaller ulcers than 
patients without helminth infections. However, the time 
for the lesion to heal was approximately double in co-
infected patients (O’Neal et al. 2007). The authors postu-
late that these effects are due to a stronger Th2-immune 
response induced by the helminth infection, which ad-
versely affects the Th1 immune response, which com-
promises host defence against Leishmania sp. infection. 
However, another study demonstrated that early intro-
duction of anti-helminthic therapy did not improve clini-
cal outcomes in patients co-infected with helminths and 
L. braziliensis (Newlove et al. 2011). 
The antigens used in this study were selected be-
cause they are secreted by the membrane and/or tegu-
ment of the S. mansoni adult worm. Proteins secreted 
or localised on the surface of Schistosoma spp, which 
are in intimate contact with host tissues, can be more 
effective at triggering immunoregulatory processes 
(Simpson et al. 1990). Our hypothesis is that these an-
tigens may reduce the Th1 response by a mechanism 
involving regulatory cells and cytokines, rather than a 
shift towards a Th2 immune response.
Since there is limited production of IL-10 in CL (Ba-
cellar et al. 2002), the use of S. mansoni antigens capa-
ble of inducing IL-10 production should be of benefit to 
these patients. Our findings show that the S. mansoni 
antigens, SmTSP-2 and PIII, were able to reduce IFN-γ 
and TNF-α production. However, there was not a large 
increase in the levels of IL-10. These results suggest that 
IL-10 production is not the only mechanism involved 
in down-modulation of the inflammatory response to 
Leishmania infection. 
Although cells from patients with CL might produce 
IFN-γ and TNF-α to delay the infection, the modula-
tion of these cytokines at the site of the lesion appears 
to be a rational strategy to limit the local exacerbated 
immune response.
In the conventional treatment with Sb(v) there is a 
prolonged healing time of three-four months. This treat-
ment has serious side effects including pancreatitis, liver 
enzyme abnormalities and cardiac arrhythmia (Berman 
1997). The association of immunomodulators, such as 
granulocyte/macrophage colony stimulating factor lo-
cally applied as adjuvant therapy in low doses, improves 
the healing of chronic ulcers (Jaschke et al. 1999). Other 
drugs, such as pentoxifylline, inhibit TNF-α synthesis 
and thus down-modulates the immune response when 
associated with antimony therapy. This results in an in-
creased cure rate and a decreased healing time of CL and 
mucosal leishmaniasis (Lessa et al. 2001, Machado et al. 
2007). Therefore, the combination of conventional treat-
ment with an immunomodulatory strategy may be more 
efficient in preventing or diminishing the tissue damage 
in CL or mucosal leishmaniasis.
In this study, we observed that patients who had 
reduced production of IFN-γ in the presence of the S. 
mansoni antigens, Sm29 and PIII, show no differences 
in clinical parameters, such as number and size of le-
sion. Additionally, there was no difference in the course 
number of antimony therapy compared to those patients 
who did not have reduced levels of IFN-γ. Patients who 
did not have reduced IFN-γ production in the presence 
862 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 106(7), November 2011
of SmTSP-2 had smaller sized lesions compared to those 
who had reduced IFN-γ production in the presence of 
this antigen. Nevertheless, there was no significant dif-
ference in the clinical parameters when we compared 
patients with reduced TNF-α production in the presence 
of the S. mansoni antigens and those who did not have 
reduced TNF-α production.
Additionally, we compared the frequency of pa-
tients who had increased levels of IL-10 and IL-5 when 
S. mansoni antigens were added to the cultures in the 
groups of patients who either had reduced production 
of IFN-γ and TNF-α or production was unaffected 
when cultured with S. mansoni antigens. We found no 
significant difference between them. These findings 
indicate that even though S. mansoni antigens are ca-
pable of inducing Th2 and T regulatory cytokine pro-
duction, other regulatory mechanisms may have a role 
in the down-modulation of Th1-inflammatory response 
in CL. Alternatively, IL-10 might be essential but not 
sufficient to regulate IFN-γ and TNF-α production. 
This concept has been demonstrated where expression 
of IL-10 receptor was impaired in mucosal leishmania-
sis (Faria et al. 2005). This could explain the results 
in our study where IL-10 did not down-regulate T cell 
responses in cells isolated from CL patients.
It has been shown that inhibition of IFN-γ produc-
tion tends to be greater at lower concentrations of this 
cytokine (Ito et al. 1999). In our study, the base levels of 
IFN-γ in response to SLA were compared between the 
group of patients who had reduced IFN-γ production with 
the addition of S. mansoni antigens to the cultures and 
those patients whose IFN-γ production was unaffected. 
No significant differences were found in the mean levels 
of IFN-γ in response to SLA in patients who had reduced 
levels of IFN-γ with the addition of Sm29 and SmTSP-2 
compared to the group who did not have reduced levels 
of IFN-γ. Unexpectedly, the base levels of IFN-γ were 
higher in patients who had reduced levels of IFN-γ with 
the addition of PIII compared to the group who did not 
have reduced levels of IFN-γ. The mean levels of TNF-α 
in response to SLA did not differ between patients based 
on the levels of expression of TNF-α that followed the 
addition of S. mansoni antigens. These data lead us to 
conclude that the base levels of pro-inflammatory cytok-
ines exert little or no influence on the immune response 
to bystander antigens in CL.
Taken together, we have shown that the S. mansoni 
antigens Sm29, SmTSP-2 and PIII induce IL-10 and IL-5 
production in CL. Additionally, these antigens are able 
to control the in vitro inflammatory response in patients 
independent of the clinical features of disease, such as 
number and size of lesions. Ongoing studies are being 
conducted to identify other regulatory mechanisms that 
may be involved in the down-modulation of the inflam-
matory response in CL. 
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